atai Life Sciences Investor Christian Angermayer Addresses Recent Trial Results And Pipeline Outlook Jan 13, 2023
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and… Mar 30, 2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program Jan 12, 2022
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021